bapineuzumab Articles
Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development
4 December 2012
Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's
24 July 2012
Intellect Neurosciences appeals European patent decision
15 December 2011
Alzheimer's drug market to more than triple to $13.3 billion in 2019 in top seven markets, fuelled by new biologic agents
10 September 2010
Showing 1-6 of 6 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
